Abstract
We report a 72-year-old man who was diagnosed by gastroscopy as having a type III poorly differentiated adenocarcinoma in the lesser curvature, with the longest diameter being 10 cm. An abdominal computed tomography (CT) scan revealed multiple liver metastases, thickening of the gastric wall, and an enlarged paraaortic lymph node. The serum carcinoembryonic antigen (CEA) level was 60 ng/ml and the carbohydrate antigen (CA) 19–9 level was 1355 U/ml. The patient received combined chemotherapy with doxifluridine (800 mg/body per day) and paclitaxel (one course comprised three weekly infusions at a dose of 70 mg/m2 followed by 1-week rest). After the completion of three courses, the patient achieved a complete response (CR), with complete disappearance of the primary tumor, the metastatic foci in the liver, and the enlarged abdominal lymph nodes; as well, the tumor markers were normalized. Adverse effects included only mild anorexia that was limited to grade 1. He maintained a CR for 1 year and 2 months. Combination chemotherapy with paclitaxel and doxifluridine can be an effective treatment for unresectable advanced gastric carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Y Yamada K Shirao A Ohtsu et al. (2001) ArticleTitlePhase II trial of paclitaxel by 3-h infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reaction Ann Oncol 12 1133–1137 Occurrence Handle11583196 Occurrence Handle10.1023/A:1011680507956 Occurrence Handle1:STN:280:DC%2BD3MrjsFehtQ%3D%3D
AD Seidman CA Hudis J Albanel et al. (1998) ArticleTitleDose-dense therapy with weekly 1-h paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 3353–3361 Occurrence Handle9779712 Occurrence Handle1:CAS:528:DyaK1cXmvFGrtbY%3D
T Arai T Hamaguchi K Shirao et al. (2003) ArticleTitleWeekly paclitaxel (PTX) in patients with heavily treated advanced gastric cancer Jpn J Cancer Clin 49 621–625
P Therasse SG Arbuck EA Eisenhauer (2000) ArticleTitleNew guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205–216 Occurrence Handle10655437 Occurrence Handle10.1093/jnci/92.3.205 Occurrence Handle1:STN:280:DC%2BD3c7it1Gitg%3D%3D
PB Schiff SB Horwitz (1981) ArticleTitleTaxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated protein Biochemistry 20 3247–3252 Occurrence Handle6113842 Occurrence Handle10.1021/bi00514a041 Occurrence Handle1:CAS:528:DyaL3MXktFyjs78%3D
P Rosenberg H Andersson K Boman et al. (2002) ArticleTitleRandomized trial of single agent paclitaxel given weekly versus every 3 weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncol 41 418–424 Occurrence Handle12442916 Occurrence Handle10.1080/028418602320404998 Occurrence Handle1:CAS:528:DC%2BD38Xpsl2ktbc%3D
A Seidman D Berry C Cirrincione et al. (2004) ArticleTitlePhase III study of weekly paclitaxel via 1-h infusion vs standard 3-h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 + MBC and randomized for trastuzumab for HER2 normal MBC Proc ASCO 23 IssueIDabstract 512
S Yamamoto Y Tanaka T Ito et al. (2003) ArticleTitleWeekly paclitaxel for a patient with advanced gastric cancer Gastric Cancer 6 117–121 Occurrence Handle12884850
Y Sakurai I Yoshida S Tonomura et al. (2003) ArticleTitleWeekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma Gastric Cancer 6 243–249 Occurrence Handle14716519 Occurrence Handle10.1007/s10120-003-0250-7
A Kono Y Hara S Sugata et al. (1983) ArticleTitleActivation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors Chem Pharm Bull 31 175–178 Occurrence Handle6221809 Occurrence Handle1:CAS:528:DyaL3sXhslamt70%3D
N Sawada T Ishikawa Y Fukase et al. (1998) ArticleTitleInduction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013–1019 Occurrence Handle9563897 Occurrence Handle1:CAS:528:DyaK1cXisFeksr4%3D
K Fujimoto-Ouchi Y Tanaka T Tominaga (2001) ArticleTitleSchedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models Clin Cancer Res 7 1079–1086 Occurrence Handle11309360 Occurrence Handle1:CAS:528:DC%2BD3MXjs1eltLk%3D
I Takeyoshi F Makita Y Tanahashi et al. (2005) ArticleTitleA combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients Anticancer Res 25 1291–1296 Occurrence Handle15865080 Occurrence Handle1:CAS:528:DC%2BD2MXkt1Wnurg%3D
S Yoshino M Oka S Hazama et al. (2004) ArticleTitleA combination phase I study of weekly paclitaxel and 5′-DFUR in patients with unresectable or recurrent gastric cancer in an outpatient setting Proc ASCO 23 IssueIDabstract 4228
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mizutani, S., Oyama, T., Hatanaka, N. et al. Unresectable gastric cancer with multiple liver metastases effectively treated with combined paclitaxel and doxifluridine chemotherapy. Int J Clin Oncol 11, 471–474 (2006). https://doi.org/10.1007/s10147-006-0597-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-006-0597-y